semaglutide patent protection Novo Nordisk to lose in Canada for Ozempic and Wegovy The semaglutide story: highlighting the

Not approved for diagnostic, therapeutic, or medical applications

Learn effective ways to manage type 2 diabetes with this medication.

A 2026 review of six studies found that people with diabetes or obesity taking GLP-1 medications were prone to developing a number of nutrient deficiencies, particularly in vitamin D, iron, and B v...

PlexusDx offers personalized semaglutide options that start at $149/month to help you find the right fit

Background Glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular benefits in type 2 diabetes, but none of the cardiovascular trials studied atrial fibrillation/atrial flutter (AF) as a primary endpoint

Understanding how they work and what sets them apart is essential before choosing any weight-loss pathway